Listed

Oramed Pharmaceuticals Inc.: Form 10-Q for the period ended Nov 30, 2021

Filed with the SEC on Jan 11, 2022 and accepted by EDGAR at Jan 11, 2022, 16:45 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-11-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-09-01 to 2021-11-30$674.0kus-gaap:Revenues
Research and development3 months2021-09-01 to 2021-11-30$6.4mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-09-01 to 2021-11-30−$8.1mus-gaap:OperatingIncomeLoss
Net income3 months2021-09-01 to 2021-11-30−$8.1mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-09-01 to 2021-11-30$0.22us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2021-09-01 to 2021-11-30−$6.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2021-11-30$31.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-11-30$152.3mus-gaap:AssetsCurrent
Total assetsAt period end2021-11-30$182.4mus-gaap:Assets
Current liabilitiesAt period end2021-11-30$7.7mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2021-11-30$11.7mus-gaap:LongTermDebt
Shareholders' equityAt period end2021-11-30$170.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-22-001563. Last ingested by Listed: Nov 15, 2026, 04:14 ET. Listed shows no prices and gives no investment advice.